GLP-1s: New daily weight loss pill Foundayo approved by UK regulator

AI Summary

The UK has approved a new daily GLP-1 pill called orforglipron (marketed as Foundayo) for weight management and type 2 diabetes, marking the first European authorization. The MHRA has authorized its private prescription use, while the NHS will consider it pending NICE's cost-effectiveness evaluation.

A new daily GLP-1 pill, orforglipron (marketed as Foundayo), has been approved by the UK’s drug regulator for weight management and type 2 diabetes.The UK is the first country in Europe to approve this glucagon-like peptide-1 receptor agonist developed by Eli Lilly.The Medicines and Healthcare Products Regulatory Agency (MHRA) authorised orforglipron for weight loss and weight maintenance in adults in the UK with a BMI of 30 or above or a BMI of between 27 and 30 and at least one weight related comorbidity.1The drug is also authorised to improve glycaemic control in patients with insufficiently controlled type 2 diabetes.The decision means orforglipron will be available with a private prescription in the UK, but the National Institute for Health and Care Excellence (NICE) will still need to recommend it before it can be prescribed on the NHS. NICE is currently evaluating its clinical and cost effectiveness, with a decision expected...